Mesothelioma In Situ
Executive Summary
Mesothelioma in situ (MIS) is a preinvasive mesothelial lesion recognized in the 2021 World Health Organization classification as a potential precursor of diffuse pleural mesothelioma.[1] It is defined by a single layer of atypical mesothelial cells lining the pleural surface, molecular alterations such as BAP1 (BRCA1-associated protein 1) or MTAP (methylthioadenosine phosphorylase) loss of expression, and the absence of stromal invasion.[1] Its formal recognition matters because, unlike most solid tumors, pleural mesothelioma was historically regarded as having no identifiable precursor lesion — a view the WHO's 2021 classification revised.
Mesothelioma in situ is not a different disease from mesothelioma and it is not a genetic or hereditary condition. It represents the earliest, pre-invasive stage of the same asbestos-related cancer, before tumor cells break through the tissue boundary. Asbestos exposure remains the established cause of mesothelioma, including its in-situ precursor; the molecular changes seen in MIS (BAP1/MTAP loss, or p53 overexpression) are diagnostic features of the lesion identified on tissue testing, not independent causes of the disease.
Because MIS can precede invasive mesothelioma, recognizing it may allow earlier identification of patients at risk of progression.[1] The published evidence is still limited to small case series and single case reports, and the authors of that work emphasize that larger prospective studies are needed before any surveillance protocol can be considered established.[1] Patients diagnosed with mesothelioma or an in-situ precursor after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims, and can review their options with an experienced mesothelioma firm.[2]
At-a-Glance
Mesothelioma in situ at a glance:
- WHO 2021 recognition — MIS was included in the 2021 World Health Organization classification of thoracic tumors as a potential precursor of diffuse pleural mesothelioma.[1]
- Defined by three criteria — a single layer of atypical mesothelial cells, loss of BAP1 or MTAP expression, and no stromal invasion.[1]
- Typical presentation — reported cases presented with unexplained, unilateral pleural effusion and lacked significant findings on ^18F-FDG PET/CT.[1]
- BAP1 loss in every case — in one published case series, BAP1 loss on immunohistochemistry was present in all cases assessed.[1]
- Diagnosis requires tissue — confirmation depends on thoracoscopic multi-site pleural biopsy with ancillary immunohistochemistry, not imaging or cytology alone.[1]
- Progression is documented — a case with an MIS-like surface component was found alongside invasive pleural mesothelioma, with concurrent BAP1 and MTAP loss in that instance.[1]
- An alternate marker exists — the first reported MIS case associated with a TP53 mutation (rather than BAP1 loss) showed p53 overexpression, suggesting p53 staining may help evaluate BAP1-retained cases.[3]
- Not a precancer of the "predisposed" — MIS is early asbestos-related disease found in tissue, not a hereditary risk state; the same asbestos exposure that causes invasive mesothelioma underlies the precursor.[4]
- Natural history still open — published authors state that larger prospective studies are needed to clarify natural history and define optimal surveillance and treatment.[1]
- Compensation may apply — an in-situ or invasive mesothelioma diagnosis linked to asbestos exposure can support trust-fund and legal claims.[5]
Key Facts
| Measure | Finding (Source) |
|---|---|
| Classification status | Recognized precursor lesion — included in the WHO 2021 classification of thoracic tumors (Pezzuto et al., Pathol Res Pract, 2026)[1] |
| Defining histology | Single layer of atypical mesothelial cells, no stromal invasion (Pezzuto et al., 2026)[1] |
| Core molecular markers | BAP1 loss and/or MTAP loss on immunohistochemistry (Pezzuto et al., 2026)[1] |
| Alternate marker | p53 overexpression in a TP53-mutated, BAP1-retained case (Churg et al., Am J Surg Pathol, 2026)[3] |
| Typical presentation | Unexplained unilateral pleural effusion, negative ^18F-FDG PET/CT (Pezzuto et al., 2026)[1] |
| Diagnostic method | Thoracoscopic multi-site biopsy + immunohistochemistry (Pezzuto et al., 2026)[1] |
| Documented progression | MIS-like surface component with invasive mesothelioma, concurrent BAP1+MTAP loss (Pezzuto et al., 2026); peritoneal TP53 case progressing to invasion (Churg et al., 2025)[1][3] |
| Underlying cause | Asbestos exposure — the same established cause as invasive mesothelioma (National Cancer Institute)[4] |
| Evidence base | Small case series and case reports; larger prospective studies needed (Pezzuto et al., 2026)[1] |
What Is Mesothelioma In Situ?
Mesothelioma in situ is the earliest, pre-invasive stage of mesothelioma — a cancer of the thin membrane (the mesothelium) that lines the chest and abdominal cavities. In an in-situ lesion, atypical mesothelial cells are present as a single layer along the pleural (or peritoneal) surface, but they have not yet invaded the underlying tissue.[1] That absence of stromal invasion is the line that separates "in situ" from invasive, diffuse mesothelioma.
For most of the modern history of the disease, pleural mesothelioma was described as a cancer without a recognized precursor lesion. That changed with the 2021 World Health Organization classification of thoracic tumors, which included mesothelioma in situ as a distinct, recognized preinvasive entity.[1] Under the WHO framework, a diagnosis of MIS rests on three integrated criteria: the characteristic single-layer atypical surface proliferation, supportive molecular findings (most often BAP1 loss or MTAP loss of expression on immunohistochemistry), and confirmation that no invasion is present.[1]
It is important to be precise about what MIS is and is not. It is early asbestos-related disease identified in tissue — not a genetic condition, a hereditary syndrome, or a marker of who is "predisposed" to cancer. The established cause of mesothelioma, including its in-situ precursor, is asbestos exposure.[4] The molecular alterations that pathologists look for in MIS are diagnostic signatures of the lesion under the microscope; they help confirm the diagnosis, and they are downstream features of the asbestos-driven disease process rather than separate causes of it.
How Is Mesothelioma In Situ Diagnosed?
Diagnosing mesothelioma in situ is difficult precisely because the lesion is so early and so subtle. In the published case series, patients presented with unexplained, unilateral pleural effusion — fluid accumulating on one side of the chest — and, notably, lacked significant findings on ^18F-FDG PET/CT imaging.[1] Because a pre-invasive lesion may not form a mass or light up on a PET scan, imaging alone cannot make the diagnosis, and neither can fluid cytology in isolation.
Confirmation depends on tissue. In the reported cases, diagnosis was made through thoracoscopic multi-site pleural biopsy — sampling several areas of the pleura during a minimally invasive procedure — followed by careful histomorphologic review and ancillary immunohistochemistry.[1] On immunohistochemistry, BAP1 loss was present in all cases assessed in one series, making it a central diagnostic marker; loss of MTAP expression provides additional supportive evidence.[1] The diagnosis requires close integration of clinical data, imaging, and pathology, which is why the authors describe it as a challenging, multidisciplinary determination rather than a single-test result.[1]
Not every case follows the usual BAP1 pattern. In a peritoneal case reported separately, BAP1, MTAP, and NF2/merlin were all retained on immunohistochemistry, yet p53 was overexpressed in the in-situ and invasive components. That case was associated with a TP53 mutation and represented the first documented example of MIS linked to TP53 rather than the typical BAP1 alteration.[3] The authors suggested that p53 staining may be useful in evaluating potential MIS cases when BAP1 is retained — a practical addition to the diagnostic toolkit for atypical presentations.[3] Adequate tissue sampling is essential throughout, because a superficial biopsy that captures only the surface component can miss invasion present deeper in the specimen.[1]
Why Does Mesothelioma In Situ Overturn the "No Precursor Lesion" View?
For most cancers, physicians can point to a recognized precursor — a pre-invasive change that precedes invasive disease, such as carcinoma in situ in other organs. Mesothelioma was long considered an exception: a cancer that appeared to arise without a documented, diagnosable precursor lesion. The formal inclusion of mesothelioma in situ in the WHO 2021 classification reframed that assumption by establishing MIS as a recognized preinvasive entity along the pathway to diffuse mesothelioma.[1]
The published case evidence supports that reframing in a concrete way. Beyond simply defining the lesion, the reports document instances where an in-situ component sits alongside — or precedes — invasive mesothelioma in the same patient.[1][3] That co-occurrence is the kind of observation that a precursor-to-cancer model predicts. It is worth stating the limits plainly: this is case-series-level evidence, drawn from small numbers of patients, and it establishes recognition of the entity rather than a fully mapped natural history.[1] The significance is conceptual and diagnostic — MIS gives pathologists and clinicians a named, criteria-based lesion to recognize — not a claim that the progression timeline or the proportion of MIS lesions that advance to invasion is yet known.
What Does Case Evidence Show About Progression to Invasive Disease?
The strongest signal that mesothelioma in situ can precede invasive disease comes from documented progression within individual cases. In the pleural case series, three patients fulfilled the diagnostic criteria for confirmed MIS.[1] In a separate patient, an initial biopsy showed a superficial proliferation compatible with MIS, but subsequent surgical sampling demonstrated invasive pleural mesothelioma with an associated MIS-like surface component — and concurrent loss of both BAP1 and MTAP expression was observed specifically in that latter case.[1] That sequence — an MIS-like surface finding accompanied by invasion on deeper sampling — is direct case evidence that the in-situ and invasive states are connected.
A second line of evidence comes from the peritoneal cavity. In a 55-year-old man, mesothelioma in situ was reported giving rise to invasive mesothelioma, associated with a long in-frame TP53 deletion, with p53 overexpression seen across the flat in-situ, papillary in-situ, and invasive components.[3] This case both documented progression and expanded the molecular picture, showing that MIS is not defined by a single genetic alteration.
These observations should be read for what they are. Case series and case reports suggest that MIS can progress to invasive mesothelioma and illustrate the heterogeneity of MIS-spectrum lesions; they do not prove a progression rate or timeline, and the authors are explicit that larger prospective studies are required to clarify the natural history.[1] The value of the evidence lies in establishing the connection and underscoring the importance of adequate tissue sampling and longitudinal follow-up.[1]
What Does Mesothelioma In Situ Mean for Surveillance and Early Detection?
The appeal of a recognized precursor lesion is the possibility of catching mesothelioma earlier. Because MIS can precede invasive disease, its recognition may allow earlier identification of patients at risk of developing invasive mesothelioma — particularly among people with a history of asbestos exposure who present with unexplained, one-sided pleural effusion and unrevealing imaging.[1] For those patients, the case evidence argues for thorough thoracoscopic sampling and immunohistochemistry rather than assuming that a negative PET/CT rules out early disease.[1]
What the evidence does not yet support is a settled surveillance protocol. The published authors state directly that larger prospective studies are needed to clarify its natural history, validate prognostic molecular markers, and define optimal surveillance and treatment approaches.[1] In practical terms, there is no validated screening pathway, no established monitoring schedule after an MIS diagnosis, and no proven treatment specific to the in-situ stage — these remain open research questions rather than standard clinical practice. Patients who have been diagnosed with mesothelioma in situ should discuss follow-up and management individually with a specialist mesothelioma team, since care must be tailored to the person rather than drawn from an established protocol.
For anyone facing an asbestos-related diagnosis — whether an in-situ precursor or invasive mesothelioma — the legal picture is more settled than the surveillance picture. A diagnosis tied to documented asbestos exposure can support claims against asbestos trust funds and, where applicable, litigation.[2][6] Reviewing exposure history and diagnostic records with an experienced mesothelioma firm is the practical next step for understanding compensation options.[5]
Frequently Asked Questions
What is mesothelioma in situ?
Mesothelioma in situ (MIS) is the earliest, pre-invasive stage of mesothelioma. It is defined by a single layer of atypical mesothelial cells on the pleural (or peritoneal) surface, supportive molecular findings such as BAP1 or MTAP loss, and the absence of stromal invasion. It was recognized as a precursor lesion in the WHO 2021 classification of thoracic tumors.[1]
How is mesothelioma in situ different from invasive mesothelioma?
The defining difference is invasion. In MIS, abnormal mesothelial cells are confined to a single surface layer and have not broken through into the underlying tissue; in invasive mesothelioma, tumor cells have penetrated the stroma and spread. MIS is the same asbestos-related disease at an earlier, pre-invasive point along its course, not a separate condition.[1][4]
Can mesothelioma be caught early through an in-situ diagnosis?
Potentially. Because MIS can precede invasive disease, recognizing it may allow earlier identification of at-risk patients — especially those with asbestos exposure and unexplained one-sided pleural effusion.[1] However, the lesion often does not show on ^18F-FDG PET/CT and requires thoracoscopic biopsy to diagnose, and there is currently no validated screening program for it. The evidence is limited to small case series, and larger studies are needed.[1]
What causes mesothelioma in situ?
Asbestos exposure is the established cause of mesothelioma, including its in-situ precursor.[4] The molecular changes pathologists look for in MIS — BAP1 loss, MTAP loss, or p53 overexpression — are diagnostic features used to identify the lesion in tissue; they are not independent or hereditary causes of the disease.[1][3]
What happens after a mesothelioma in situ diagnosis?
Because there is no established surveillance protocol or in-situ-specific treatment, management is individualized. Patients should be evaluated by a specialist mesothelioma team for close follow-up, since case evidence shows MIS can progress to invasive disease and adequate tissue sampling matters.[1] A diagnosis linked to asbestos exposure may also support compensation claims through asbestos trust funds and legal action.[2]
Is mesothelioma in situ hereditary or genetic?
No. MIS is early asbestos-related disease found in tissue, not a hereditary or inherited condition. Molecular markers such as BAP1 or TP53 findings in these cases are alterations identified within the lesion to support diagnosis; they do not make MIS a genetic disease, and asbestos exposure remains the underlying cause.[3][4]
Quick Statistics
- 2021 — year the WHO classification of thoracic tumors recognized mesothelioma in situ as a precursor lesion.[1]
- 3 — patients who fulfilled diagnostic criteria for confirmed MIS in the published pleural case series.[1]
- 100% — proportion of assessed cases in that series showing BAP1 loss on immunohistochemistry.[1]
- 1st — the TP53-associated case represented the first documented MIS example linked to TP53 rather than BAP1.[3]
- 0 — validated surveillance protocols currently established for MIS; larger prospective studies are still needed.[1]
- 55 — age, in years, of the man in the reported peritoneal MIS-to-invasion case.[3]
External Links
- Danziger & De Llano — Mesothelioma Resources — overview of mesothelioma diagnosis, asbestos exposure, and the trust-fund claim process
- Mesothelioma Lawyers Near Me — filing guides and attorney directory for asbestos-related claims
- Mesothelioma.net — patient resources, diagnosis and treatment information, and compensation guides
- Mesothelioma Lawyer Center — medical background on diagnosis and legal claim information
Related Pages
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 1.24 1.25 1.26 1.27 1.28 1.29 1.30 1.31 1.32 1.33 1.34 1.35 1.36 1.37 1.38 1.39 1.40 1.41 1.42 1.43 1.44 1.45 Pezzuto F, Giraudo C, Biondini D, Pontoriero FM, Fortarezza F, Faccioli E, Pasello G, Dell'Amore A, Calabrese F. Mesothelioma in situ-spectrum pleural lesions: Diagnostic challenges and longitudinal follow-up in a case series. Pathol Res Pract. 2026;285:156522.
- ↑ 2.0 2.1 2.2 Mesothelioma Resources, Danziger & De Llano.
- ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 Churg A, Haase E, Siddiqui R, Ng T. Mesothelioma in Situ With a TP53 Mutation. Am J Surg Pathol. 2026;50(2):267-271.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Malignant Mesothelioma, National Cancer Institute.
- ↑ 5.0 5.1 Mesothelioma Diagnosis and Legal Information, Mesothelioma Lawyer Center.
- ↑ Mesothelioma Patient Resources, Mesothelioma.net.